WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2009140642) TRICYCLIC ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2009/140642    International Application No.:    PCT/US2009/044219
Publication Date: 19.11.2009 International Filing Date: 15.05.2009
IPC:
C07D 487/04 (2006.01), C07D 487/02 (2006.01), A61K 31/445 (2006.01), A61P 11/00 (2006.01), A61P 29/00 (2006.01)
Applicants: AMIRA PHARMACEUTICALS, INC. [US/US]; 9535 Waples Street Suite 100 San Diego, CA 92121 (US) (For All Designated States Except US).
HUTCHINSON, John, Howard [US/US]; (US) (For US Only).
STEARNS, Brian, Andrew [US/US]; (US) (For US Only).
CLARK, Ryan [US/US]; (US) (For US Only)
Inventors: HUTCHINSON, John, Howard; (US).
STEARNS, Brian, Andrew; (US).
CLARK, Ryan; (US)
Agent: AKHAVAN, Ramin; (US)
Priority Data:
61/054,093 16.05.2008 US
61/107,638 22.10.2008 US
Title (EN) TRICYCLIC ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS
(FR) ANTAGONISTES TRICYCLIQUES DE RÉCEPTEURS DE PROSTAGLANDINE D2
Abstract: front page image
(EN)Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions and medicaments that include the compounds described herein that are antagonists of PGD2 receptors. Also described herein are methods of using such antagonists of PGD2 receptors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2-mediated conditions or diseases.
(FR)L'invention concerne des composés qui sont des antagonistes de récepteurs de PGD2. Des compositions pharmaceutiques et des médicaments qui comprennent les composés décrits ici, qui sont des antagonistes de récepteurs de PGD2, sont également décrits. Des procédés sont également décrits pour l'utilisation de tels antagonistes de récepteurs de PGD2, seuls ou en combinaison avec d'autres composés, pour un traitement d'états ou de maladies respiratoires, cardiovasculaires et autres,  dépendantes de PGD2 ou à médiation par PGD2.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)